{"entity":{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","aka":[],"tldr":"A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy is a phase 3 interventional study registered as NCT01874353 by AstraZeneca, with 327 participants enrolled, started 2013-09-03 and due to reach its primary completion in 2016-09-19. Interventions recorded: Olaparib 300mg tablets and Placebo to match olaparib 300mg. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01874353","url":"https://clinicaltrials.gov/study/NCT01874353"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-sensitive-ovarian-cancer"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":["astrazeneca","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01874353","phase":"3","setting":"Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy","sponsor":"AstraZeneca","started":"2013-09-03","startedType":"actual","yearReported":2018,"enrolled":327,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)","primary":true,"unit":"months","arms":[{"name":"Olaparib 300mg Tablets (Global Cohort)","n":196,"value":19.1,"note":"95% CI 16.3 to 25.7; Figures from the ClinicalTrials.gov results section (first posted 2018-02-07), not from a publication"},{"name":"Placebo Tablets (Global Cohort)","n":99,"value":5.5,"note":"95% CI 5.2 to 5.8"},{"name":"Olaparib 300mg Tablets (China Cohort)","n":22,"value":13.8,"note":"95% CI 6.5 to 16.6"},{"name":"Placebo Tablets (China Cohort)","n":10,"value":5.5,"note":"95% CI 2.7 to NA"}],"source":"https://clinicaltrials.gov/study/NCT01874353?tab=results"}]},"route":"/trials/nct01874353/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}